CONCLUSIONS
ASSOCIATED CONDITIONS, HYPERTENSION
Sacubitril/valsartan has recently been approved in Japan and China for the treatment of hypertension. This analysis provides the first data on the differential effects of treatment with sacubitril/valsartan on ambulatory BP in patient subgroups based on the nocturnal BP dipping status. It also confirms the potent 24‐hour BP‐lowering effects of sacubitril/valsartan in Asian populations with hypertension. Strict reduction in 24‐hour BP and maintaining the dipper pattern of nocturnal BP are critical components of strategies designed to achieve perfect 24‐hour BP control, which is essential to attenuate or prevent hypertension‐mediated target organ damage and associated conditions.